Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir

Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Doehle BP, Pang PS, Chuang SM, Ma J, Ding X, Afdhal NH, et al. Gastroenterology. 2016 June 11th ed. 2016;151(3):501-512.E1.

Publication Type:

Journal Article

Authors:

Sarrazin, C.; Dvory-Sobol, H.; E. S. Svarovskaia; et, al

Source:

Gastroenterology, Volume 151, Issue 3, p.501-512.E1 (2016)

Cited On:

HCV Resistance Primer

External Third-party Web Link:

https://www.ncbi.nlm.nih.gov/pubmed/27296509

Export Citation:

RIS Format

Top